FDA Regulatory Capture by Pharma

Overview

In 2004, David Graham, a twenty-year veteran safety officer at the FDA, sat before a Senate committee and said something that federal employees almost never say: his employer was broken. “The FDA, as currently configured, is incapable of protecting America against another Vioxx,” he testified. The arthritis drug had just been pulled from the market after causing an estimated 27,785 heart attacks and sudden cardiac deaths. Graham claimed the agency had known about the risks and suppressed them.

He wasn’t a crank. He wasn’t a conspiracy theorist. He was the FDA’s own associate director for science in the Office of Drug Safety. And the story he told — of an agency structurally incentivized to approve drugs rather than question them, of internal dissenters being sidelined, of a revolving door between the people writing the rules and the people profiting from them — is one that has only gained more supporting evidence in the two decades since.

The theory of FDA regulatory capture is unusual in the conspiracy landscape because large parts of it are simply documented fact. The pharmaceutical industry does fund the majority of the FDA’s drug review operations. Officials do cycle between the agency and the industry. Drugs have been approved and then withdrawn after causing deaths. The question is not whether these things happen — they demonstrably do — but whether they constitute a deliberate conspiracy or merely the predictable dysfunction of an underfunded regulatory system operating under political pressure.

Origins & History

The modern story of FDA-pharma entanglement begins on October 29, 1992, with the passage of the Prescription Drug User Fee Act, known as PDUFA. The law was born of frustration: AIDS activists had spent years protesting the FDA’s glacially slow drug approval process, and the agency was drowning in an application backlog with a congressional budget that hadn’t kept pace. The solution was elegantly simple and, critics would later argue, catastrophically corrupting: let the pharmaceutical companies pay.

Under PDUFA, drug makers would pay user fees — starting at around $100,000 per application and rising over the years to more than $3 million — to fund FDA reviewer positions. In exchange, the FDA committed to strict timelines for reviewing applications. The backlog cleared. Approval times dropped from an average of 30 months in the early 1990s to under 12 months by the 2000s.

But something else changed too. Before PDUFA, the FDA’s Center for Drug Evaluation and Research (CDER) derived most of its operating budget from congressional appropriations. By 2022, industry user fees accounted for approximately 65% of the human drug review budget. The agency’s single largest funder was no longer the American taxpayer. It was the pharmaceutical industry.

The revolving door predated PDUFA, but the user fee era supercharged it. As former FDA commissioner Herbert Ley had warned back in 1969: “The thing that bugs me is that the people think the FDA is protecting them. It isn’t. What the FDA is doing and what the public thinks it’s doing are as different as night and day.”

The OxyContin Approval

No single case better illustrates the revolving-door concern than OxyContin. In 1995, FDA medical officer Curtis Wright oversaw the review and approval of Purdue Pharma’s new extended-release oxycodone formulation. The approved label included a remarkable sentence: the drug’s delayed absorption was “believed to reduce the abuse liability.” This claim was not supported by the clinical data Purdue had submitted. No studies had been conducted comparing OxyContin’s abuse potential with other opioids.

That single sentence became one of the most consequential pieces of regulatory language in American history. Sales representatives used it to assure doctors that OxyContin was safer than other painkillers. Prescriptions exploded. Within two decades, more than 200,000 Americans would be dead from prescription opioid overdoses.

And Curtis Wright? Roughly a year after leaving the FDA, he accepted a position at Purdue Pharma, where he was paid approximately $400,000 in his first year. The Government Accountability Office later found no evidence that Wright violated existing ethics rules — which tells you everything you need to know about the rules.

Vioxx and the Safety Office Revolt

The Vioxx disaster of 2004 became the defining scandal of FDA regulatory capture. Merck’s blockbuster arthritis drug, approved in 1999, was generating $2.5 billion in annual revenue when mounting evidence indicated it was causing heart attacks and strokes. FDA safety officer David Graham conducted an analysis showing that Vioxx had caused between 88,000 and 139,000 heart attacks, of which 27,785 were fatal.

Graham later testified that his superiors in the Office of New Drugs actively pressured him to soften his findings. The institutional culture, he explained, treated drug approval as a mission and safety concerns as obstacles. His testimony led to calls for structural reform — some of which were implemented, many of which were not.

Key Claims

• Financial capture through user fees. The pharmaceutical industry funds approximately 65% of the FDA’s drug review budget through PDUFA user fees, creating a structural dependency in which the agency’s funding depends on maintaining a steady flow of approvals. Review deadlines incentivize speed over thoroughness.

• The revolving door corrupts decision-making. A 2018 BMJ study found that 11 of 16 FDA reviewers who left the agency between 2001 and 2010 went to work for or consult with the companies they had reviewed. Current officials make decisions knowing that their future employers are watching.

• Accelerated approval is exploited. The Accelerated Approval pathway, created in 1992 for serious conditions with unmet needs, has been increasingly used for drugs with marginal benefits. A 2021 study found that many drugs approved through this pathway never completed confirmatory trials, remaining on the market based on surrogate endpoints rather than proven clinical benefit.

• Post-market safety signals are suppressed. Critics allege the agency is structurally biased toward keeping approved drugs on the market. The Office of New Drugs (which approves drugs) has historically held more institutional power than the Office of Surveillance and Epidemiology (which monitors safety).

• Advisory committee conflicts of interest are routine. FDA advisory committee members frequently have financial relationships with the companies whose drugs they are evaluating. While conflict-of-interest waivers are supposed to be rare, studies have found they are granted liberally.

Evidence & Analysis

What Is Documented Fact

The structural issues are not in dispute. PDUFA’s funding model is public law. The revolving door statistics are published in peer-reviewed journals. The OxyContin label language and Curtis Wright’s subsequent employment at Purdue are matters of congressional record. The Vioxx death toll estimates come from the FDA’s own safety officer. A 2017 study published in JAMA found that 71 of 222 drugs approved between 2001 and 2010 — nearly one in three — had postmarket safety events including black box warnings, safety communications, and withdrawals. These are facts.

The GAO, the Office of the Inspector General, and multiple congressional committees have all documented various forms of the revolving door and its effects. In 2006, the Institute of Medicine issued a report titled “The Future of Drug Safety” that called for sweeping reforms, including greater independence for the safety office and mandatory registration of clinical trials.

Where Conspiracy Overreaches

The documented failures of the FDA do not, however, support the more expansive conspiracy claims frequently attached to them. Some versions of the theory posit that the FDA deliberately approves drugs it knows are dangerous as part of a coordinated scheme between government officials and pharmaceutical executives to profit from illness. This version collapses the distinction between structural dysfunction and active malice — between a system that produces bad outcomes because of misaligned incentives and a system that is designed to produce bad outcomes.

The reality is considerably more mundane and, in some ways, more troubling. The FDA employs thousands of scientists who genuinely believe they are protecting public health. The problem is not that these people are corrupt but that the institution they work in has been gradually restructured — through funding mechanisms, political pressure, and cultural incentives — in ways that systematically favor the interests of the industry over the interests of patients.

This is the textbook definition of regulatory capture, a concept described by economist George Stigler in 1971 — not as a conspiracy but as the predictable outcome of concentrated industry interests overwheliming diffuse public interests.

Notable Drug Withdrawals and Safety Failures

Cultural Impact

The FDA regulatory capture narrative has become one of the most influential conspiracy-adjacent ideas in American politics — partly because so much of it is verifiable. It has been embraced across the political spectrum, though for different reasons. The political left tends to frame it as a corporate accountability issue, citing the revolving door and the influence of lobbying. The political right, particularly during and after the COVID-19 pandemic, has used it to justify blanket skepticism toward FDA-approved vaccines and treatments.

The narrative has been amplified by several high-profile cultural products. Journalist Gerald Posner’s Pharma: Greed, Lies, and the Poisoning of America (2020) documented the industry’s influence on regulation. The Hulu series Dopesick (2021) dramatized the OxyContin approval process, including Curtis Wright’s role, for a mass audience. Patrick Radden Keefe’s Empire of Pain (2021) further cemented the Sackler-Purdue-FDA nexus in public consciousness.

The theory’s cultural influence is most visible in declining public trust in pharmaceutical regulators. Gallup polling shows trust in the FDA dropping from 48% in 2020 to 34% by 2023. While multiple factors contribute, the regulatory capture narrative — and the documented evidence supporting parts of it — is a significant driver.

The concern among public health officials is that legitimate criticisms of the FDA’s structure are being weaponized to undermine trust in all drug regulation, including vaccines and treatments where the evidence of safety and efficacy is robust. This is the paradox of the regulatory capture narrative: it is true enough to be corrosive, and corrosive enough to be dangerous.

Timeline

• 1906 — Pure Food and Drug Act creates the precursor to the FDA
• 1937 — Sulfanilamide disaster kills 107 people; leads to 1938 Federal Food, Drug, and Cosmetic Act
• 1961 — Thalidomide scandal strengthens FDA authority (Kefauver-Harris Amendment, 1962)
• 1969 — Former FDA commissioner Herbert Ley warns the agency is failing its mission
• 1992 — PDUFA passes; pharmaceutical companies begin funding FDA drug reviews
• 1995 — OxyContin approved with “reduced abuse liability” label language
• 1997 — FDA Modernization Act further relaxes approval standards
• 1999 — Vioxx approved
• 2001 — Curtis Wright’s move from FDA to Purdue Pharma becomes public
• 2004 — Vioxx withdrawn; David Graham testifies before Senate about FDA safety failures
• 2006 — Institute of Medicine report calls for sweeping FDA reform
• 2007 — FDA Amendments Act gives agency some additional post-market authority
• 2012 — FDA Safety and Innovation Act reauthorizes PDUFA V
• 2017 — JAMA study finds one-third of approved drugs had post-market safety issues
• 2018 — BMJ study documents revolving door between FDA reviewers and industry
• 2020 — COVID-19 pandemic puts FDA approval processes under intense public scrutiny
• 2021 — Controversial approval of Aduhelm (Alzheimer’s drug) despite advisory committee opposition prompts resignations
• 2023 — Multiple accelerated-approval drugs withdrawn or challenged for failing to complete confirmatory studies

Sources & Further Reading

• Graham, David. Senate Finance Committee Testimony on Vioxx and FDA Safety, November 18, 2004
• Pham-Kanter, Genevieve. “Revisiting Financial Conflicts of Interest in FDA Advisory Committees.” Milbank Quarterly, 2014
• Moynihan, Ray et al. “FDA advisors’ financial ties to industry.” BMJ, 2018
• Downing, Nicholas S. et al. “Postmarket Safety Events Among Novel Therapeutics Approved by the US FDA.” JAMA, 2017
• Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. National Academies Press, 2006
• Posner, Gerald. Pharma: Greed, Lies, and the Poisoning of America. Avid Reader Press, 2020
• Keefe, Patrick Radden. Empire of Pain: The Secret History of the Sackler Dynasty. Doubleday, 2021
• Carpenter, Daniel. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, 2010
• Stigler, George J. “The Theory of Economic Regulation.” Bell Journal of Economics, 1971

Related Theories

• Big Pharma Conspiracy — broader theories about pharmaceutical industry malfeasance
• Pharmaceutical Suppression — claims that effective treatments are suppressed to protect profits
• Opioid Crisis Pharma Conspiracy — the role of pharmaceutical companies in the opioid epidemic
• Monsanto Roundup — another case of alleged regulatory capture involving the EPA and agrochemical industry
• Anti-Vaccination Movement — how FDA skepticism feeds into broader vaccine hesitancy